The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications
If these are optimized, discuss with your provider about confirming your dose is appropriate or exploring whether a different medication or combination therapy might better match your genetic pathway response
Understanding the role of GLP-1 in the body and how it can help with blood sugar regulation and weight loss is integral to our approach at Set Point
Initial clinical trials appeared to validate the beneficial effect of incretins, specifically: A small open-label Phase 1 study (2013) with exenatide (Byetta, twice daily, beginning with 5 g/dose for a month and then increased to 10 g/dose) in 45 patients with PD of moderate severity
Labs provide the objective data that symptoms can't: actual hormone levels, metabolic markers, and the clinical context that determines whether TRT, Compounded Tirzepatide, or both are appropriate for you specifically